Mds 2024 Parkinson'S Disease. Estimates of the risk of dementia in parkinson's disease (pdd) vary widely. This document presents the movement disorder society clinical diagnostic criteria for parkinson's disease (pd).


Mds 2024 Parkinson'S Disease

The poster will be presented by irlab’s director of clinical science & biometrics, fredrik hansson, and susanna waters, director of systems pharmacology,. This trial’s primary and secondary endpoints evaluate buntanetap’s impact on motor function as measured by the movement disorder society.

Mds 2024 Parkinson'S Disease Images References :